Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 1:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 560 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Clear all
Active, not recruiting Phase 2 Interventional

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

NCT04753879
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 7, 2026, 1:59 AM EDT
Terminated No phase listed Observational

Freehand Ultrasound Elasticity Imaging in Liver Surgery

NCT00942383
View directory record Official record
Conditions
Liver Tumors
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Jun 7, 2026, 1:59 AM EDT
Withdrawn Phase 1 Interventional

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

NCT02875002
View directory record Official record
Conditions
Relapsed and Refractory Aggressive B- and T-cell Lymphomas, Lymphoma
Interventions
volasertib, belinostat
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
New Haven, Connecticut • Baltimore, Maryland • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Jun 7, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional Results available

Study of Stereotactic Radiotherapy for Breast Cancer

NCT03043794
View directory record Official record
Conditions
Breast Cancer
Interventions
Stereotactic Body Radiation Therapy SBRT
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 7, 2026, 1:59 AM EDT
Terminated Not applicable Interventional Results available

Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma

NCT00631137
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Musculoskeletal Complications
Interventions
testosterone gel applied to skin, whey powder protein
Drug · Dietary Supplement
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2018 · Synced Jun 7, 2026, 1:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer

NCT01496157
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFBC
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Jun 7, 2026, 1:59 AM EDT
Completed No phase listed Observational

Topical Application of Sulforaphane-containing Broccoli Sprout Extracts on Radiation Dermatitis

NCT00894712
View directory record Official record
Conditions
Breast Cancer, Dermatitis
Interventions
Sulforaphane-containing broccoli sprout extracts (active agent), Vehicle (inactive control)
Other · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Jun 7, 2026, 1:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

NCT01203722
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Fludarabine, Cytoxan, Total Body Irradiation, Allogeneic Blood or Marrow Transplant, Peripheral Blood Stem Cell Transplant, Mycophenolate Mofetil, Sirolimus, Tacrolimus
Drug · Radiation · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 75 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jun 7, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional Results available

Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin

NCT02096588
View directory record Official record
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Simvastatin, Doxorubicin/cyclophosphamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Jun 7, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers

NCT04037358
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radium-223, stereotactic ablative radiotherapy (SABR)
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Jun 7, 2026, 1:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer

NCT01815515
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
18F-DCFBC
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2018 · Synced Jun 7, 2026, 1:59 AM EDT
Completed Early Phase 1 Interventional

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

NCT01861340
View directory record Official record
Conditions
Myeloma
Interventions
Lenalidomide, Dexamethasone, and MEDI-551
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jun 7, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional Results available

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

NCT00276744
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cetuximab, capecitabine, docetaxel, Erlotinib, Gemcitabine, Irinotecan, mitomycin C, rapamycin, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Jun 7, 2026, 1:59 AM EDT
Active, not recruiting Phase 1 Interventional

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

NCT03961971
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
MBG453
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Stanford, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jun 7, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional Results available

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

NCT03420521
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoid Tumor
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Jun 7, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

NCT02601014
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Ipilimumab, Nivolumab, Enzalutamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Jun 7, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

NCT00303927
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
capecitabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2010 · Synced Jun 7, 2026, 1:59 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Radiation Therapy for Pediatric Sarcomas

NCT01763970
View directory record Official record
Conditions
Sarcoma, Metastatic Disease, Bony Sites
Interventions
SBRT
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
4 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
5
States / cities
Stanford, California • Washington D.C., District of Columbia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Jun 7, 2026, 1:59 AM EDT
Terminated Phase 1 Interventional Results available

A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

NCT01701375
View directory record Official record
Conditions
Relapsed Acute Leukemia, Refractory Acute Leukemia, High-Risk Myelodysplasia
Interventions
PD 0332991
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Jun 7, 2026, 1:59 AM EDT
Active, not recruiting Phase 2 Interventional

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

NCT02451982
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Cyclophosphamide, GVAX pancreatic cancer, Nivolumab, Urelumab, BMS-986253
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 7, 2026, 1:59 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

NCT00024466
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GVAX, Autologous transplant
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Jun 7, 2026, 1:59 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

NCT02845323
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Nivolumab in combination with Urelumab, Nivolumab monotherapy
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jun 7, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional Results available

Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT

NCT00068770
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
radiation therapy, Celecoxib
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
7
States / cities
Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Jun 7, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

NCT00489281
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cyclophosphamide, Fludarabine, Mycophenolate mofetil, Sirolimus, Allogeneic bone marrow transplant, Total body irradiation - 200, Levetiracetam, Anti-thymocyte globulin, Total body irradiation - 400
Drug · Procedure · Radiation + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
2 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jun 7, 2026, 1:59 AM EDT